Sign In
Buy FMS
$25.66
-0.0400 (-0.156%)
At Close: Jul 31, 2026
Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up
11:18am, Friday, 03'rd Nov 2023
Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2023 Earnings Call Transcript
04:51pm, Thursday, 02'nd Nov 2023
Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2023 Earnings Call Transcript
Top Medical Stocks to Buy Amid Recent Market Volatility
07:33pm, Monday, 23'rd Oct 2023
Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare i
Are Investors Undervaluing Fresenius Medical Care AG & Co. (FMS) Right Now?
11:18am, Friday, 20'th Oct 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Here's Why You Should Retain Fresenius Medical (FMS) for Now
09:01am, Monday, 16'th Oct 2023
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Fresenius Medical: use of drugs like Ozempic has neutral effect on dialysis patient numbers
12:14pm, Thursday, 12'th Oct 2023
Germany's Fresenius Medical Care , said that use of Ozempic, and other diabetes and weight-loss drugs of the same class, would have an overall neutral effect on how many patients will require the comp
What other industries could weight loss drugs disrupt?
07:10pm, Wednesday, 11'th Oct 2023
Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.
Why Dialysis Stocks Plunged Today
12:51pm, Wednesday, 11'th Oct 2023
Novo Nordisk shares rallied after it announced it will stop its FLOW trial nearly a year earlier than expected after positive feedback on interim data for semaglutide's ability to treat kidney disease
Why Shares of Fresenius Medical Care Were Dropping on Wednesday
12:18pm, Wednesday, 11'th Oct 2023
Novo Nordisk ended a phase 3 trial early for Ozempic for preventing kidney disease because the trial was so successful. Fresenius and other dialysis-connected companies saw their shares fall on Wednes
Ozempic Is Moving a Bunch of Stocks Wednesday Morning
09:37am, Wednesday, 11'th Oct 2023
Markets were poised to move higher again on Wednesday morning. Shares of Novo Nordisk climbed on good news from a study of its drug Ozempic on kidney patients.
Dialysis company shares plunge after Ozempic trial success vs. kidney trouble
03:59am, Wednesday, 11'th Oct 2023
The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.
Here's Why You Should Retain Fresenius Medical (FMS) for Now
09:46am, Friday, 15'th Sep 2023
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Fresenius Medical's (FMS) New HHD Device to Increase Portability
09:46am, Thursday, 24'th Aug 2023
Fresenius Medical (FMS) gets FDA clearance for Versi HD with GuideMe Software, a portable, home hemodialysis device with an easy-to-use graphical interface providing easier training experiences.
Fresenius Medical (FMS) Q2 Earnings and Revenues Beat Estimates
12:00pm, Thursday, 03'rd Aug 2023
Fresenius Medical's (FMS) second-quarter revenues benefit from strong performance across all segments. Inflationary pressure continues to improve, benefiting operating income.
Fresenius Medical Care AG & Co. KGaA (FMS) Q2 2023 Earnings Call Transcript
03:47pm, Wednesday, 02'nd Aug 2023
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q2 2023 Earnings Conference Call August 2, 2023 9:30 AM ET Company Participants Dominik Heger - Head of Investor Relations Helen Giza - Chief Executive
